Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany.
German Center for Infection Research (DZIF), Partner site Hamburg-Lübeck-Borstel-Riems, Hamburg, Germany.
Nature. 2020 Oct;586(7830):509-515. doi: 10.1038/s41586-020-2787-6. Epub 2020 Sep 23.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the aetiological agent of coronavirus disease 2019 (COVID-19), an emerging respiratory infection caused by the introduction of a novel coronavirus into humans late in 2019 (first detected in Hubei province, China). As of 18 September 2020, SARS-CoV-2 has spread to 215 countries, has infected more than 30 million people and has caused more than 950,000 deaths. As humans do not have pre-existing immunity to SARS-CoV-2, there is an urgent need to develop therapeutic agents and vaccines to mitigate the current pandemic and to prevent the re-emergence of COVID-19. In February 2020, the World Health Organization (WHO) assembled an international panel to develop animal models for COVID-19 to accelerate the testing of vaccines and therapeutic agents. Here we summarize the findings to date and provides relevant information for preclinical testing of vaccine candidates and therapeutic agents for COVID-19.
严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)是 2019 年冠状病毒病(COVID-19)的病原体,这是一种由新型冠状病毒于 2019 年末传入人体引起的新发呼吸道感染病(首次在中国湖北省发现)。截至 2020 年 9 月 18 日,SARS-CoV-2 已传播至 215 个国家,感染了超过 3000 万人,并导致超过 95 万人死亡。由于人类对 SARS-CoV-2 没有预先存在的免疫力,因此迫切需要开发治疗药物和疫苗,以减轻当前的大流行并防止 COVID-19 的再次出现。2020 年 2 月,世界卫生组织(WHO)成立了一个国际小组,以开发用于 COVID-19 的动物模型,从而加速疫苗和治疗药物的测试。在这里,我们总结了迄今为止的研究结果,并为 COVID-19 候选疫苗和治疗药物的临床前测试提供了相关信息。